Under construction – not a live service
Sign in
Taking people in NetherlandsNo phase

Urine Tests Checking Kidney Tubules in Chronic Kidney Disease

Tests urine markers of kidney tubule function in adults with stage 3 chronic kidney disease.

Plain-language title generated from the registry record
Registry title: Urinary Tubular Biomarkers for Chronic Kidney Disease

Key facts

Where
Rotterdam, NetherlandsSee the site

Where in Netherlands

  • Erasmus MCRotterdam, NetherlandsTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Erasmus Medical Center
Trial code
NCT06732349
Record updated
7 August 2025
Original description
Currently used tests for chronic kidney injury only assess the function of one part of the kidney: the filter called the glomerulus. The other part, called the tubule, is disregarded. Based on many previous studies, the investigators have good reason to assume that a better prediction of the course of chronic kidney disease by testing tubular function will be possible. This is important, for example, when patients need to be treated with kidney-protecting drugs.Read full original descriptionShow less

Urinary Tubular Biomarkers for Chronic Kidney Disease

Currently used tests for chronic kidney injury only assess the function of one part of the kidney: the filter called the glomerulus. The other part, called the tubule, is disregarded. Based on many previous studies, the investigators have good reason to assume that a better prediction of the course of chronic kidney disease by testing tubular function will be possible. This is important, for example, when patients need to be treated with kidney-protecting drugs.

Inclusion: Chronic kidney disease stage 3 (eGFR 30-59ml/min).

Exclusion: Active glomerulonephritis treated with immunosuppression; Kidney transplant recipient; Current treatment with chemo- or immunotherapy for malignancy.

ClinicalTrials.gov NCT06732349